{"id":860428,"date":"2025-06-13T10:04:48","date_gmt":"2025-06-13T14:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/"},"modified":"2025-06-13T10:04:48","modified_gmt":"2025-06-13T14:04:48","slug":"iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/","title":{"rendered":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n LOS ANGELES<\/span>
\n <\/span>, June 13, 2025<\/span><\/span> \/PRNewswire\/ — The DJS Law Group<\/a>\u00a0reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) for violations of the federal securities laws.<\/p>\n

\n

\n
\n \"DJS
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Shareholders\u00a0who purchased the Company’s securities between May 9, 2024<\/span> and May 8, 2025<\/span>, inclusive (the “Class Period”), are encouraged to contact the firm before July 14<\/span>, 2025.\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n CASE DETAILS:<\/b>\u00a0\u00a0The complaint alleges<\/span> that the Company made false and misleading statements to the market concerning whether Iovance’s new Authorized Treatment Centers (“ATCs”) suffered from longer timelines to begin treatment with Amtagvi than expected. The Company’s sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company’s failure to match ATCs with manufactured product led to lower revenues and higher costs.<\/p>\n

If you are a shareholder who suffered a loss,\u00a0contact us to participate<\/a>.<\/p>\n

\n WHY DJS LAW GROUP?<\/b>\u00a0DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\n CONTACT:<\/b>\n <\/p>\n

\n David J. Schwartz<\/span>\n <\/p>\n

DJS Law Group<\/p>\n

274 White Plains Road, Suite 1<\/p>\n

\u00a0Eastchester, NY 10709<\/p>\n

Phone: 914-206-9742<\/p>\n

Email:\u00a0David@djslawllp.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit—contact-the-djs-law-group-to-discuss-your-rights—elv-302480908.html<\/a><\/p>\n

SOURCE DJS Law Group LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES , June 13, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before July 14, 2025.\u00a0\u00a0\u00a0\u00a0 CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning whether Iovance’s new Authorized Treatment Centers (“ATCs”) suffered from longer timelines to begin treatment with Amtagvi than expected. The Company’s sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company’s failure to match ATCs … <\/p>\n

Continue reading “IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES , June 13, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before July 14, 2025.\u00a0\u00a0\u00a0\u00a0 CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning whether Iovance’s new Authorized Treatment Centers (“ATCs”) suffered from longer timelines to begin treatment with Amtagvi than expected. The Company’s sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company’s failure to match ATCs … Continue reading "IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-13T14:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV\",\"datePublished\":\"2025-06-13T14:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/\"},\"wordCount\":290,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2710314\\\/DJS_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/\",\"name\":\"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2710314\\\/DJS_Logo.jpg\",\"datePublished\":\"2025-06-13T14:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2710314\\\/DJS_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2710314\\\/DJS_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/","og_locale":"en_US","og_type":"article","og_title":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk","og_description":"PR Newswire LOS ANGELES , June 13, 2025 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or “the Company”) (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders\u00a0who purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before July 14, 2025.\u00a0\u00a0\u00a0\u00a0 CASE DETAILS:\u00a0\u00a0The complaint alleges that the Company made false and misleading statements to the market concerning whether Iovance’s new Authorized Treatment Centers (“ATCs”) suffered from longer timelines to begin treatment with Amtagvi than expected. The Company’s sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company’s failure to match ATCs … Continue reading \"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-13T14:04:48+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV","datePublished":"2025-06-13T14:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/"},"wordCount":290,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/","name":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg","datePublished":"2025-06-13T14:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2710314\/DJS_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit-contact-the-djs-law-group-to-discuss-your-rights-elv-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit – Contact the DJS Law Group to Discuss Your Rights – ELV"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}